Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
After finishing at $65.06 in the prior trading day, Guardant Health Inc (NASDAQ: GH) closed at $61.36, down -5.69%. In other words, the price has decreased by -$5.69 from its previous closing price. On the day, 4.7 million shares were traded. GH stock price reached its highest trading level at $61.48 during the session, while it also had its lowest trading level at $57.51.
Ratios:
Our goal is to gain a better understanding of GH by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.35 and its Current Ratio is at 3.71.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Mizuho on April 10, 2025, initiated with a Outperform rating and assigned the stock a target price of $55.
On January 23, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $60.
Guggenheim Upgraded its Neutral to Buy on June 28, 2024, while the target price for the stock was maintained at $36.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 02 ’25 when Joyce Meghan V. sold 100 shares for $65.84 per share. The transaction valued at 6,584 led to the insider holds 11,183 shares of the business.
Joyce Meghan V. bought 100 shares of GH for $6,584 on Sep 02 ’25. On Aug 21 ’25, another insider, Kalia Kumud, who serves as the Chief Information Officer of the company, sold 2,000 shares for $61.76 each. As a result, the insider received 123,510 and left with 18,500 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GH now has a Market Capitalization of 7651960320 and an Enterprise Value of 8463296512. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.23. Its current Enterprise Value per Revenue stands at 10.211 whereas that against EBITDA is -20.193.
Stock Price History:
The Beta on a monthly basis for GH is 1.56, which has changed by 1.5857565 over the last 52 weeks, in comparison to a change of 0.20221436 over the same period for the S&P500. Over the past 52 weeks, GH has reached a high of $68.00, while it has fallen to a 52-week low of $20.14. The 50-Day Moving Average of the stock is 16.69%, while the 200-Day Moving Average is calculated to be 38.67%.
Shares Statistics:
The stock has traded on average 2.43M shares per day over the past 3-months and 2272620 shares per day over the last 10 days, according to various share statistics. A total of 124.48M shares are outstanding, with a floating share count of 118.53M. Insiders hold about 4.95% of the company’s shares, while institutions hold 100.20% stake in the company. Shares short for GH as of 1755216000 were 8187779 with a Short Ratio of 3.36, compared to 1752537600 on 9582594. Therefore, it implies a Short% of Shares Outstanding of 8187779 and a Short% of Float of 6.890000000000001.
Earnings Estimates
The stock of Guardant Health Inc (GH) is currently drawing attention from 13.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.48, with high estimates of -$0.4 and low estimates of -$0.55.
Analysts are recommending an EPS of between -$1.74 and -$1.97 for the fiscal current year, implying an average EPS of -$1.88. EPS for the following year is -$1.64, with 16.0 analysts recommending between -$1.25 and -$2.21.
Revenue Estimates
18 analysts predict $235.59M in revenue for the current quarter. It ranges from a high estimate of $240M to a low estimate of $231.6M. As of the current estimate, Guardant Health Inc’s year-ago sales were $191.48MFor the next quarter, 18 analysts are estimating revenue of $250.45M. There is a high estimate of $254.4M for the next quarter, whereas the lowest estimate is $247.4M.
A total of 22 analysts have provided revenue estimates for GH’s current fiscal year. The highest revenue estimate was $928.52M, while the lowest revenue estimate was $915.8M, resulting in an average revenue estimate of $922.07M. In the same quarter a year ago, actual revenue was $739.02MBased on 22 analysts’ estimates, the company’s revenue will be $1.12B in the next fiscal year. The high estimate is $1.17B and the low estimate is $1.08B.
